A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
Status:
Terminated
Trial end date:
2017-03-22
Target enrollment:
Participant gender:
Summary
PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy
and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes
that do not appear to be clearly disabling. Participants will be randomized in a 1:1 ratio to
receive within 3 hours of last known well time either 1) one dose of IV alteplase and one
dose of oral aspirin placebo or 2) one dose of IV alteplase placebo and one dose of oral
aspirin 325 milligrams (mg).